You are here

Fundamentally New Therapeutic for the Treatment of Acinetobacter Baumannii Wound Infections

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-06-C-0008
Agency Tracking Number: A052-170-0771
Amount: $117,969.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: A05-170
Solicitation Number: 2005.2
Solicitation Year: 2005
Award Year: 2005
Award Start Date (Proposal Award Date): 2005-11-14
Award End Date (Contract End Date): 2006-05-13
Small Business Information
505 S. Rosa Road, Suite 29, Madison, WI, 53719
DUNS: 084322598
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Hideki Suzuki
 Director of Microbiology
 (608) 441-2794
Business Contact
 Salvatore Braico
Title: Chief Operating Officer
Phone: (608) 441-2890
Research Institution
An increasing number of infections caused by the pathogenic and multi-drug-resistant bacterium Acinetobacter baumannii has been reported in patients at military medical facilities in which service members were injured in the Iraq/Kuwait region during Operation Iraqi Freedom and in Afghanistan during Operation Enduring Freedom. Due to their drug resistance, these infections have been difficult to treat. ConjuGon is developing a fundamentally new antibacterial technology that is able to kill virtually all Gram negative pathogens, regardless of their antibiotic resistance. We have extensive in vitro and in vivo data demonstrating the ability of this technology to effectively kill multi- and pan-resistant bacteria such as A. baumannii and Pseudomonas aeruginosa. ConjuGon is developing a topical antibacterial product, based on this technology, to be used to treat large wound infections such as those affecting military personnel.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government